Prosecution Insights
Last updated: November 04, 2026
Application No. 16/615,552

Recombinant Protein

Final Rejection §112
Filed
Nov 21, 2019
Priority
May 24, 2017 — GB 1708277.7 +1 more
Examiner
ROBINSON, HOPE A
Art Unit
1652
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
GE Healthcare Bioprocess R&D AB
OA Round
8 (Final)
68%
Grant Probability
Favorable
9-10
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 68% — above average
68%
Career Allowance Rate
717 granted / 1060 resolved
+7.6% vs TC avg
Strong +43% interview lift
Without
With
+42.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
64 currently pending
Career history
1141
Total Applications
across all art units

Statute-Specific Performance

§101
6.8%
-33.2% vs TC avg
§103
19.4%
-20.6% vs TC avg
§102
17.0%
-23.0% vs TC avg
§112
50.3%
+10.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1060 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AlA or AIA Status 1. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . 2. The Amendment filed on July 27, 2026, has been received and entered. Claim Disposition 3. Claims 2-3, 5, 7-9, 11 and 13-35 are cancelled. Claims 36-39 have been added. Claims 1, 4, 6, 10, 12 and 36-39 are pending and are under examination. Claim Objection 4. Claims 1, 4, 6, 10, 12 and 36-39 are objected to for the following informalities: For clarity and precision of claim language it is suggested that claim 1 is amended to read, A [[partially]] purified recombinant protein expressed in a gram-negative [[gram negative]] bacteria comprising an N-terminal spacer linked to [[a functional polypeptide, wherein the functional polypeptide is ]] an immunoglobulin binding polypeptide comprising an immunoglobulin binding domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-11, and wherein the [[functional]] polypeptide comprises one or more Fc-binding domains obtained from Staphylococcus aureus Protein A, and wherein the N-terminal spacer comprises [[the]] an amino acid sequence selected from the group consisting of SEQ ID NOs: 16-18, 29-30, 33-34, 37-40, and 43-45-33-40, 43-45. For clarity it is suggested that claims 4 and 12 are amended to read, “The recombinant protein of claim 1, wherein the [[functional]] polypeptide comprises….”. The dependent claims hereto are also included. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. 5. Claims 1, 4, 6, 10, 12 and 36-39 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre- AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for pre-AlA the inventor(s), at the time the application was filed, had possession of the claimed invention. The claimed invention as amended is directed to “a partially purified recombinant protein expressed in gram negative bacteria comprising an N-terminus spacer linked to a functional polypeptide, wherein the functional polypeptide is an immunoglobulin binding polypeptide comprising an immunoglobin binding domain having an amino acid sequence…. (see claim 1 in its entirety), however, the claim language has no functional limitation per se for the protein. The recitation of the language ‘functional’ is a mere assertion and does not really endow a specific activity especially with a protein that is recombinantly made. There are no indicia that the native activity for instance is retained. The claimed invention as set forth in claim 1 encompasses a large variable genus of structures since an immunoglobulin protein has multiple domains; and only provides the structure of the spacer and a domain but not the entire fusion protein. No correlation is made between structure and function. Having the structure of the spacer does not give an ordinary skilled worker a glimpse of the structure of the recombinant protein and the same is true for the domain. Thus the claim is completely devoid of functional limitations aligned with a specific structure for the recombinant protein. Therefore, no correlation is made between structure and function. The claim language broadly reads on any recombinant protein from any source and any length with no requirement for activity. Therefore, no correlation is made between structure and function for the protein and claim 1 needs to stand on its own. The claimed invention as a whole encompasses a large variable genus of structures and organisms and lacks functional limitation. The specification discloses E. coli, however the claims encompass a large variable genus of gram-negative bacteria. The dependent claims hereto do not rectify the missing information. One of ordinary skill in the art would not have a glimpse of the recombinant polypeptide with just knowing the two amino acids on the N-terminal spacer or that the Fc-binding polypeptide alpha helix has 14-24 amino acids, for example. What is the structure and function of the ‘recombinant protein’ claimed? The claimed invention as amended is directed to “a partially purified recombinant protein expressed in gram negative bacteria”, however, the specification does not have this language. The specification discloses at paragraph [0090] that, “As the skilled person will understand, the expressed recombinant protein should be purified to an appropriate extent before being immobilized to a support”. Thus this represents new matter, and making the specification lack adequate written description. The specification fails to provide any additional representative species of the claimed genus to show that applicant was in possession of the claimed genus. A representative number of species means that the species which are adequately described are representative of the entire genus. The written description requirement for a claimed genus may be satisfied through sufficient description of a representative number of species by actual reduction to practice, disclosure of drawings, or by disclosure of relevant identifying characteristics, for example, structure or other physical and/or chemical properties, by functional characteristics coupled with a known or disclosed correlation between function and structure, or by a combination of such identifying characteristics, sufficient to show the applicant was in possession of the claimed genus. In addition, critical information is missing from for example, claim 10 to achieve an alkali-stabilized Fc-binding domain, thus the claimed invention is not adequately described. The 'written description' requirement.., serves both to satisfy the inventor's obligation to disclose the technologic knowledge upon which the patent is based, and to demonstrate that the patentee was in possession of the invention that is claimed ....The descriptive text needed to meet these requirements varies with the nature and scope of the invention at issue, and with the scientific and technologic knowledge already in existence." Capon v. Eshhar, 418 F.3d 1349, 1357 (Fed. Cir. 2005). The purpose of the written description requirement "is to ensure that the scope of the right to exclude ... does not overreach the scope of the inventor's contribution to the field of art as described in the patent specification." Reiffin v. Microsoft Corp., 214 F.3d 1342, 1345-46 (Fed. Cir. 2000). The goal of the written description requirement is "to clearly convey the information that an applicant has invented the subject matter which is claimed." In re Barker, 559 F.2d 588, 592 n.4 (CCPA 1977) "A disclosure in an application, to be complete, must contain such description and details as to enable any person skilled in the art or science to which the invention pertains to make and use the invention as of its filing date." In re Glass, 492 F.2d 1228, 1232 (CCPA 1974). Additionally, Vas-Cath Inc. v. Mahurkar, 935 F.2d 1555, 1563-64, 19 USPQ2d 1111, 1117 (Fed. Cir.1991), states that "applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of the invention. The invention is, for purposes of the 'written description' inquiry, whatever is now claimed" (See page 1117). The specification does not "clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is claimed" (See Vas-Cath at page 1116). The skilled artisan cannot envision the detailed chemical structure of the encompassed genus of polypeptides, and therefore, conception is not achieved until reduction to practice has occurred, regardless of the complexity or simplicity of the method of isolation. Adequate written description requires more than a mere statement that it is part of the invention and reference to a potential method of isolating it. The compound itself is required. See Fiers v. Revel, 25 USPQ2d 1601 at 1606 (CAFC 1993). Accordingly, in the absence of sufficient recitation of distinguishing identifying characteristics, the specification does not provide adequate written description of the claimed genus. Therefore, for all these reasons the specification lacks adequate written description, and one of skill in the art cannot reasonably conclude that the applicant had possession of the claimed invention at the time the instant application was filed. Response to Arguments 6. Applicant’s comments have been considered in full. Withdrawn objections/rejections will not be discussed herein as applicant’s comments are moot. Note that the rejections of record under 112, first paragraph remains for the reasons stated above and has herein been amended to reflect changes made to the claims. Applicant traverses the rejection by stating that the claims as amended requires a functional polypeptide, however, a product claim must have structure and function and applicant simply recites the language ‘functional’ but does not per se state what function is assigned to the invention being claimed. Thus the rejection remains. Conclusion 7. No claims are presently allowable, however, SEQ ID NOs: 16-18, 29-30, 33-34, 37-40 and 43-45 full length are free of the prior art. 8. Applicant’s amendment necessitated the new/modified ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to HOPE A ROBINSON whose telephone number is (571) 272-0957. The examiner can normally be reached 9-5pm on Monday to Friday. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Robert Mondesi can be reached on (408) 918-7584. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /HOPE A ROBINSON/Primary Examiner, Art Unit 1652
Read full office action

Prosecution Timeline

Show 25 earlier events
Jan 18, 2026
Response after Non-Final Action
Jan 18, 2026
Response after Non-Final Action
Apr 09, 2026
Non-Final Rejection mailed — §112
Jul 02, 2026
Applicant Interview (Telephonic)
Jul 02, 2026
Interview Requested
Jul 02, 2026
Examiner Interview Summary
Jul 27, 2026
Response Filed
Oct 06, 2026
Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12781202
RECOMBINANT HUMAN DIAMINE OXIDASE AND METHODS FOR TREATMENT OF EXCESS HISTAMINE CONDITIONS USING THE SAME
5y 2m to grant Granted Nov 03, 2026
Patent 12781213
A METHOD OF PRODUCING UNSATURATED HYDROCARBON COMPOUNDS WITH MUTATED FERULIC ACID FROM SACCHAROMYCES
4y 7m to grant Granted Nov 03, 2026
Patent 12723241
CHIMERIC THERMOSTABLE AMINOACYL-TRNA SYNTHETASE FOR ENHANCED UNNATURAL AMINO ACID INCORPORATION
4y 4m to grant Granted Sep 01, 2026
Patent 12715898
MOLECULAR PEPTIDE MUTANT
3y 2m to grant Granted Aug 25, 2026
Patent 12703859
NOVEL BRANCHED-CHAIN AMINO ACID AMINOTRANSFERASE VARIANT AND METHOD FOR PRODUCING ISOLEUCINE USING THE SAME
3y 2m to grant Granted Aug 11, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

9-10
Expected OA Rounds
68%
Grant Probability
99%
With Interview (+42.9%)
3y 3m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 1060 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month